Hemantane

Hemantane
Clinical data
Other names	Hymantane; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine
Identifiers
	IUPAC name 1-(2-adamantyl)azepane;
PubChem CID	9838302;
ChemSpider	8014022;
Chemical and physical data
Formula	C16H27N
Molar mass	233.399 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCCN(CC1)C2C3CC4CC(C3)CC2C4;
	InChI InChI=1S/C16H27N/c1-2-4-6-17(5-3-1)16-14-8-12-7-13(10-14)11-15(16)9-12/h12-16H,1-11H2; Key:JAROVUWOMYMQCW-UHFFFAOYSA-N;

Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed.^[1] It was developed and studied in Russia.^[1]

It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum.^[1]^[2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects.^[1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation.^[1]

The drug was first described by 2000.^[3]^[4]

References

^ ^a ^b ^c ^d ^e Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN 1819-7124.
^ Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology. 13: 927703. doi:10.3389/fphar.2022.927703. PMC 9574013. PMID 36263121.
^ Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 3–6. PMID 11109514.
^ Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 64 (6): 13–16. PMID 11871228.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AbaimovKovalev2011-1] Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN 1819-7124.

[FischlerSoykaSeifritz2022-2] Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology. 13: 927703. doi:10.3389/fphar.2022.927703. PMC 9574013. PMID 36263121.

[Val'dman2000-3] Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 3–6. PMID 11109514.

[AndiarzhanovaVal'dmanKudrin2001-4] Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 64 (6): 13–16. PMID 11871228.

[1]

[2]

[3]

[4]

Hemantane

See also

References